**Devising new strategies to track and prevent breast cancer development in BRCA mutation carriers**  
**Joan Brugge** | _Harvard Ludwig Cancer Center and Harvard Medical School_
* How do basal and luminal breast cells contribute to BRCA-related cancers?
* How do BRCA tumor cells evolve?
* What are the molecular defects during tumor evolution?
* How do we detection cancer evolution in carriers?
* How do we intercept and eradicate tumor development?

---

**Dissecting early pathogenesis of BRCA1/2-associated cancer for risk prediction and prevention**  
**Leif Ellisen** | _Harvard Medical School, Massachusetts General Hospital Cancer Center_
* What are the early changes in cells of BRCA carrier breast tissue?
* What are the BRCA cellular vulnerabilities?
* What are tissue-based markers for prevention approaches?

---

**Interplay and perturbations of the local microbiome and host immune system in breast cancer**  
**Charis Eng** | _Cleveland Clinic_
* What are the differences in microbes found with normal versus BRCA breast cancers?
* How do microbes contribute to immune changes 
and cancer?
* Could microbiome engineering prevent cancer?

---

**Determinants of immune activity and molecular features in BRCA1/2 mutation carriers**  
**Katherine Nathanson** | _University of Pennsylvania_
* What are the immune functional status in BRCA carriers?
* Are there associations between molecular and immune status with therapeutic response and survival?

---

**Dissection of BRCA-mediated Tumor Suppression Pathways**  
**Patrick Sung** | _Univ. of Texas Health Science Center at San Antonio_
* What are the regulators of BRCA function?
* What are BRCA-independent DNA repair pathways?
* What are the DNA repair mechanisms?
* What are the drug vulnerabilities of BRCA deficient cells?

---

**Early detection of cancer in high-risk BRCA mutation carriers using liquid biopsies**  
**Victor Velculescu** | _Johns Hopkins University_
* What are the molecular characteristics of circulation free DNA in BRCA carriers with and without cancer?
* What is the strategy for screening?
